Genentech enrolling patients for Lucentis clinical trial

Genentech, South San Francisco, CA, announced that the biotechnologycompany is enrolling patients into a Phase III clinical trial for its age-relatedmacular degeneration (AMD) drug Lucentis (ranibizumab, rhuFab V2).

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.